Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04452357 · ClinicalTrials.gov registry record · NA
Pulse-low-dose Rate (PLDR) Radiation in Pancreatic Cancer
A NA study of Pancreatic Cancer, sponsored by Fox Chase Cancer Center.
- Active
- Registry status
- NA
- Development phase
- 12
- Enrollment target
- 1
- Study location
NCT04452357: Active NA study of Pancreatic Cancer, sponsored by Fox Chase Cancer Center.
NCT04452357 is a NA study of Pancreatic Cancer that is active but no longer recruiting, run by Fox Chase Cancer Center. The registered enrollment target is 12 participants, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04452357, a NA study of Pancreatic Cancer, is active but no longer recruiting, sponsored by Fox Chase Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 12 participants
- Enrollment target
- 1
- Study location
Study Summary
Standard chemoradiation, followed by surgery are standard treatment plan for patients suffering from pancreatic adenocarcinoma. Due to damage to the surrounding healthy tissue caused by standard radiation, this study uses a new type of radiation plan- pulsed low-dose rate (PLDR) radiation , in combination with chemotherapeutic drug, gemcitabine, given weekly along with the radiation.
Primary Outcome
Number of participants with Grade 3 toxicity related to the treatment
Conditions Studied
Interventions
- RADIATION PLDR
Study Locations (1)
Pennsylvania
- Fox Chase Cancer Center - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2020-01-13 |
| Est. Completion | 2025-12-01 |
| Phase | NA |
What the registry record for NCT04452357 still lists
NCT04452357 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Pancreatic Cancer appearing as the primary indexed condition, and to 1 intervention - of which PLDR is the first listed.
NCT04452357 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT04452357 about?
NCT04452357 is a clinical study titled "Pulse-low-dose Rate (PLDR) Radiation in Pancreatic Cancer". Standard chemoradiation, followed by surgery are standard treatment plan for patients suffering from pancreatic adenocarcinoma. Due to damage to the surrounding healthy tissue caused by standard radiation, this study uses a new type of radiation plan- pulsed low-dose rate (PLDR) radiation , in combi...
What is the current status of trial NCT04452357?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 12 participants. The study started on 2020-01-13. Estimated completion is 2025-12-01.
What conditions does trial NCT04452357 study?
This clinical trial studies the following conditions: Pancreatic Cancer.
What interventions are being tested in trial NCT04452357?
The interventions under investigation include: PLDR (RADIATION).
Who is sponsoring clinical trial NCT04452357?
This trial is sponsored by Fox Chase Cancer Center, which has 183 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04452357 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreatic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04452357's enrollment target sits among peer trials
12 256th of 278 higher than 19 of 278 other Pancreatic Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pancreatic Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Alpha Radiation Emitters Device for the Treatment of Pancreatic Cancer With Chemotherapy for the Treatment of Locally Advanced and Metastatic Pancreatic Cancer
RECRUITING · NA
-
A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue
RECRUITING · NA
-
EUS Examination Using EndoSound Vision System vs. Standard Echoendoscope
RECRUITING · NA
-
Computed Tomography in Diagnosing Patients With Pancreatic or Hepatobiliary Cancer
RECRUITING · NA
-
Support Through Remote Observation and Nutrition Guidance Program (STRONG-PCS)
RECRUITING · NA
-
GENOCARE: A Prospective, Randomized Clinical Trial of Genotype-Guided Dosing Versus Usual Care
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI